Systemic hypertension affects the heart, and to the best of our knowledge, no study has investigated the effects of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in dogs with myxomatous mitral valve disease (MMVD) stage B and systemic hypertension. This study aimed to investigate the blood level of NT-proBNP and assess the selected echocardiographic variables in dogs with MMVD stage B according to the presence of systemic hypertension or normal blood pressure and in dogs without MMVD. The study group comprised 37 dogs with stage B MMVD (normotensive group, n = 30; systemic hypertension group, n = 7) and 13 dogs without MMVD. We evaluated NT-proBNP, blood pressure, complete blood count (CBC), and serum chemistry in all 50 dogs. We performed electrocardiography, radiography, and echocardiography on 44 dogs (37 dogs with MMVD and 7 dogs without MMVD). The NT-proBNP concentrations showed significant intergroup differences (p < 0.001). Normotensive dogs with MMVD stage B (median [interquartile range]: 1083.5 [574.8–1912.8] pmol/L) and hypertensive dogs with MMVD stage B (2345.0 [1812.5–2533.0] pmol/L) showed significantly higher NT-proBNP concentrations than dogs without MMVD (504 [430–774] pmol/L, p = 0.009 and p < 0.001, respectively), and dogs in the systemic hypertension group showed significantly higher NT-proBNP concentrations than those in the normotensive group (p = 0.046). Mitral valve regurgitation velocity was significantly higher in dogs in the systemic hypertension group (6.11 [6.07–6.24] m/s) than in those in the normotensive group (5.53 [5.17–5.95] m/s, p = 0.006). The left atrial to aortic root ratio (LA/Ao), E-peak velocity, and left ventricular end‐diastolic internal diameter corrected for body weight (LVIDDN) were significantly lower in dogs without MMVD than in dogs with MMVD stage B. These findings suggest that NT-proBNP concentrations are higher in dogs with MMVD stage B with systemic hypertension than in normotensive dogs with MMVD stage B. Therefore, clinicians should be aware that NT-proBNP could be elevated in the presence of systemic hypertension.

中文翻译：

---

患有粘液瘤二尖瓣疾病 B 期的正常血压和高血压犬的 N 末端前 B 型钠尿肽水平

系统性高血压会影响心脏，据我们所知，尚无研究调查 N 末端 B 型利钠肽前体 (NT-proBNP) 对患有粘液瘤二尖瓣疾病 (MMVD) B 期和全身性高血压的犬的影响高血压。本研究旨在调查 NT-proBNP 的血液水平，并根据系统性高血压或正常血压的存在评估 B 期 MMVD 犬和无 MMVD 犬的选定超声心动图变量。研究组包括 37 只患有 B 期 MMVD 的狗（正常血压组，n = 30；全身性高血压组，n = 7）和 13 只没有 MMVD 的狗。我们评估了所有 50 只狗的 NT-proBNP、血压、全血细胞计数 (CBC) 和血清化学。我们进行了心电图、射线照相、对 44 只狗（37 只患有 MMVD 的狗和 7 只没有 MMVD 的狗）进行超声心动图检查。NT-proBNP 浓度显示出显着的组间差异 (p < 0.001)。MMVD B 期血压正常的狗（中位数[四分位数范围]：1083.5 [574.8–1912.8] pmol/L）和 MMVD B 期高血压狗（2345.0 [1812.5–2533.0] pmol/L）显示出显着高于狗的 NT-proBNP 浓度无 MMVD（504 [430–774] pmol/L，分别为 p = 0.009 和 p < 0.001），而全身性高血压组的犬的 NT-proBNP 浓度显着高于正常血压组（p = 0.046）。全身性高血压组犬的二尖瓣反流速度 (6.11 [6.07–6.24] m/s) 明显高于血压正常组 (5.53 [5.17–5.95] m/s，p = 0.006)。